TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...
Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...
Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...
Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...
EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...
BMO Capital Markets agreed to pay more than $40 million to settle U.S. Securities and Exchange Commission charges it failed ...
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant ...
The big sell-off came after activist short seller Scorpion Capital released a scathing report about TransMedics. Scorpion stated in its report, "TransMedics is the most extreme and grotesque ...
On January 10, 2025, Bloomberg reported TransMedics shares dropped“as much as 13% after Scorpion Capital said it is short the transplant-therapy company's stock.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback